Transplantation Research Center, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
Biochem Biophys Res Commun. 2010 Nov 26;402(4):711-7. doi: 10.1016/j.bbrc.2010.10.091. Epub 2010 Oct 25.
Circulating tumor cells (CTC) have been identified in several human malignancies, including malignant melanoma. However, whether melanoma CTC are tumorigenic and cause metastatic progression is currently unknown. Here, we isolate for the first time viable tumorigenic melanoma CTC and demonstrate that this cell population is capable of metastasis formation in human-to-mouse xenotransplantation experiments. The presence of CTC among peripheral blood mononuclear cells (PBMC) of murine recipients of subcutaneous (s.c.) human melanoma xenografts could be detected based on mRNA expression for human GAPDH and/or ATP-binding cassette subfamily B member 5 (ABCB5), a marker of malignant melanoma-initiating cells previously shown to be associated with metastatic disease progression in human patients. ABCB5 expression could also be detected in PBMC preparations from human stage IV melanoma patients but not healthy controls. The detection of melanoma CTC in human-to-mouse s.c. tumor xenotransplantation models correlated significantly with pulmonary metastasis formation. Moreover, prospectively isolated CTC from murine recipients of s.c. melanoma xenografts were capable of primary tumor initiation and caused metastasis formation upon xenotransplantation to secondary murine NOD-scid IL2Rγ(null) recipients. Our results provide initial evidence that melanoma CTC are tumorigenic and demonstrate that CTC are capable of causing metastatic tumor progression. These findings suggest a need for CTC eradication to inhibit metastatic progression and provide a rationale for assessment of therapeutic responses of this tumorigenic cell population to promising emerging melanoma treatment modalities.
循环肿瘤细胞(CTC)已在多种人类恶性肿瘤中被鉴定出来,包括恶性黑色素瘤。然而,黑色素瘤 CTC 是否具有致瘤性并导致转移进展目前尚不清楚。在这里,我们首次分离出具有活力的致瘤性黑色素瘤 CTC,并证明该细胞群体能够在人源至鼠源异种移植实验中形成转移。可以根据人 GAPDH 和/或 ABCB5 (先前被证明与人患者的转移性疾病进展相关的恶性黑色素瘤起始细胞的标志物)的 mRNA 表达,从接受皮下(s.c.)人黑色素瘤异种移植物的鼠受者的外周血单核细胞(PBMC)中检测到 CTC 的存在。ABCB5 表达也可以在来自人 IV 期黑色素瘤患者的 PBMC 制剂中检测到,但在健康对照中则没有。在人源至鼠源 s.c.肿瘤异种移植模型中检测到黑色素瘤 CTC 与肺转移形成显著相关。此外,从接受 s.c.黑色素瘤异种移植物的鼠受者中前瞻性分离的 CTC 能够进行原发性肿瘤起始,并在异种移植到次级鼠 NOD-scid IL2Rγ(null)受者时引起转移形成。我们的研究结果初步证明了黑色素瘤 CTC 具有致瘤性,并证明了 CTC 能够引起转移性肿瘤进展。这些发现表明需要消除 CTC 以抑制转移进展,并为评估这种致瘤性细胞群体对有前途的新兴黑色素瘤治疗方法的治疗反应提供了依据。